PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Promising early results for new ovarian cancer drug combo

Results from an early-stage clinical trial found a new combination of target drugs could provide a new treatment option for treatment-resistant advanced ovarian cancer.

The Phase I FRAME trial – led by researchers at The Institute of Cancer Research, London (ICR) and The Royal Marsden NHS Foundation Trust – evaluated VS-6766 and defactinib in 25 patients with low-grade serous ovarian cancer.

Overall, 46% of patients experienced their tumours shrinking ‘significantly’ in response to treatment, with responses in patients with a KRAS mutation ‘even more promising’.

Close to two-thirds of patients with a KRAS mutation (64%) saw their tumour shrink following treatment, suggesting that tumour profiling could be used to identify which patients are more likely to benefit from the drug combination.

In addition, participants in the FRAME trial lived an average of 23 months before their cancer progressed.

“Overcoming cancer’s ability to evolve resistance to treatment is a huge challenge for cancer research. This study has turned a deep understanding of how cancer fuels its growth and develops resistance into a highly targeted treatment for patients who currently have few treatment options,” said Professor Kristian Helin, chief executive of ICR.

“Scientists have been working to develop treatments that can effectively target KRAS-driven cancers for decades. It’s fantastic that early trials indicate this treatment is highly effective for this patient group, and that a phase II trial has already begun,” he added.

Low-grade serous ovarian cancer is a rare form of cancer that typically develops at an earlier age than other types of ovarian cancer.

This uncommon type of cancer rarely responds to chemotherapy or hormone therapy, with less than 13% of patients responding to chemotherapy and less than 14% responding to hormone therapy.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026